The impact of Meth A fibrosarcoma derived EMAP II on dendritic cell migration

Cytokine

Volumn 44, Issue 2, 2008, Pages 304-309

  Haridas, Seema ^a   Bowers, Mary ^a   Tusano, Jackie ^a   Mehojah, Justin ^a   Kirkpatrick, Megan ^a   Burnham, D Kim ^a  

^a OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

Dendritic cells; EMAP II; Fibrosarcoma; Migration; Tumor

Indexed keywords

ENDOTHELIAL MONOCYTE ACTIVATING POLYPEPTIDE II; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; ASCITES; CELL CULTURE; CELL LINE; CELL MIGRATION; DENDRITIC CELL; EAR; EPIDERMIS CELL; FEMALE; FIBROSARCOMA; LANGERHANS CELL; METH A FIBROSARCOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, NEOPLASM; CELL MOVEMENT; CYTOKINES; DENDRITIC CELLS; FEMALE; FIBROSARCOMA; GROWTH INHIBITORS; HISTOCOMPATIBILITY ANTIGENS; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASM PROTEINS; RECOMBINANT PROTEINS; RNA-BINDING PROTEINS;

MUS;

EID: 55749083195     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2008.09.002     Document Type: Article

References (35)

1. Schuler G. Epidermal Langerhans cells (1991), CRC Press, Boca Raton, FL
2. Schuler G., Thurner B., and Romani N. Dendritic cells: from ignored cells to major players in T cell-mediated immunity. Int Arch Allergy Immunol 112 (1997) 317-322
3. Schaerli P., Willimann K., Ebert L.M., Walz A., and Moser B. Cutaneous CXCL14 targets blood precursors to epidermal niches for Langerhans cell differentiation. Immunity 23 (2005) 331-342
4. Inaba K., Inaba M., Romani N., Aya H., Deguchi M., Ikehara S., et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176 (1992) 1693-1702
5. Caux C., Dezutter-Dambuyant C., Schmitt D., and Banchereau J. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 360 (1992) 258-261
6. Tas M.P., Simons P.J., Balm F.J., and Drexhage H.A. Depressed monocyte polarization and clustering of dendritic cells in patients with head and neck cancer: in vitro restoration of this immunosuppression by thymic hormones. Cancer Immunol Immunother 36 (1993) 108-114
7. Thurnher M., Radmayr C., Ramoner R., Ebner S., Bock G., Klocker H., et al. Human renal-cell carcinoma tissue contains dendritic cells. Int J Cancer 68 (1996) 1-7
8. Gabrilovich D.I., Ciernik I.F., and Carbone D.P. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol 170 (1996) 101-110
9. Gabrilovich D.I., Corak J., Ciernik I.F., Kavanaugh D., and Carbone D.P. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 3 (1997) 483-490
10. Almand B., Resser J.R., Lindman B., Nadaf S., Clark J.I., Kwon E.D., et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6 (2000) 1755-1766
11. Della Bella S., Gennaro M., Vaccari M., Ferraris C., Nicola S., Riva A., et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer 89 (2003) 1463-1472
12. Hoffmann T.K., Muller-Berghaus J., Ferris R.L., Johnson J.T., Storkus W.J., and Whiteside T.L. Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin Cancer Res 8 (2002) 1787-1793
13. Esche C., Subbotin V.M., Hunter O., Peron J.M., Maliszewski C., Lotze M.T., et al. Differential regulation of epidermal and dermal dendritic cells by IL-12 and Flt3 ligand. J Invest Dermatol 113 (1999) 1028-1032
14. Gabrilovich D.I., Ishida T., Nadaf S., Ohm J.E., and Carbone D.P. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 5 (1999) 2963-2970
15. Ishida T., Oyama T., Carbone D.P., and Gabrilovich D.I. Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors. J Immunol 161 (1998) 4842-4851
16. Nestle F.O., Burg G., Fah J., Wrone-Smith T., and Nickoloff B.J. Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am J Pathol 150 (1997) 641-651
17. Ghiringhelli F., Puig P.E., Roux S., Parcellier A., Schmitt E., Solary E., et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 202 (2005) 919-929
18. Gabrilovich D.I. Mechanisms and functional significance of tumor-induced dendritic cell defects. Nat Rev Immunol 4 (2004) 941-952
19. Kao J., Ryan J., Brett G., Chen J., Shen H., Fan Y.G., et al. Endothelial monocyte-activating polypeptide II. A novel tumor-derived polypeptide that activates host-response mechanisms. J Biol Chem 267 (1992) 20239-20247
20. Murray J.C., Clauss M., Denekamp J., and Stern D. Selective induction of endothelial cell tissue factor in the presence of a tumour-derived mediator: a potential mechanism of flavone acetic acid action in tumour vasculature. Int J Cancer 49 (1991) 254-259
21. Shalak V., Kaminska M., Mitnacht-Kraus R., Vandenabeele P., Clauss M., and Mirande M. The EMAPII cytokine is released from the mammalian multisynthetase complex after cleavage of its p43/proEMAPII component. J Biol Chem 276 (2001) 23769-23776
22. van Horssen R., Eggermont A.M., and ten Hagen T.L. Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes. Cytokine Growth Factor Rev 17 (2006) 339-348
23. Kao J., Houck K., Fan Y., Haehnel I., Libutti S.K., Kayton M.L., et al. Characterization of a novel tumor-derived cytokine. Endothelial-monocyte activating polypeptide II. J Biol Chem 269 (1994) 25106-25119
24. Kao J., Fan Y.G., Haehnel I., Brett J., Greenberg S., Clauss M., et al. A peptide derived from the amino terminus of endothelial-monocyte-activating polypeptide II modulates mononuclear and polymorphonuclear leukocyte functions, defines an apparently novel cellular interaction site, and induces an acute inflammatory response. J Biol Chem 269 (1994) 9774-9782
25. Hou Y., Plett P.A., Ingram D.A., Rajashekhar G., Orschell C.M., Yoder M.C., et al. Endothelial-monocyte-activating polypeptide II induces migration of endothelial progenitor cells via the chemokine receptor CXCR3. Exp Hematol 34 (2006) 1125-1132
26. Schwarz M.A., Kandel J., Brett J., Li J., Hayward J., Schwarz R.E., et al. Endothelial-monocyte activating polypeptide II, a novel antitumor cytokine that suppresses primary and metastatic tumor growth and induces apoptosis in growing endothelial cells. J Exp Med 190 (1999) 341-354
27. Tandle A.T., Mazzanti C., Alexander H.R., Roberts D.D., and Libutti S.K. Endothelial monocyte activating polypeptide-II induced gene expression changes in endothelial cells. Cytokine 30 (2005) 347-358
28. Lans T.E., ten Hagen T.L., van Horssen R., Wu P.C., van Tiel S.T., Libutti S.K., et al. Improved antitumor response to isolated limb perfusion with tumor necrosis factor after upregulation of endothelial monocyte-activating polypeptide II in soft tissue sarcoma. Ann Surg Oncol 9 (2002) 812-819
29. Clarijs R., Schalkwijk L., Ruiter D.J., and de Waal R.M. EMAP-II expression is associated with macrophage accumulation in primary uveal melanoma. Invest Ophthalmol Vis Sci 44 (2003) 1801-1806
30. Murray J.C., Symonds P., Ward W., Huggins M., Tiga A., Rice K., et al. Colorectal cancer cells induce lymphocyte apoptosis by an endothelial monocyte-activating polypeptide-II-dependent mechanism. J Immunol 172 (2004) 274-281
31. DeLeo A.B., Shiku H., Takahashi T., John M., and Old L.J. Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma. J Exp Med 146 (1977) 720-734
32. Schuler G., and Steinman R.M. Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro. J Exp Med 161 (1985) 526-546
33. Kellermann S.A., Hudak S., Oldham E.R., Liu Y.J., and McEvoy L.M. The CC chemokine receptor-7 ligands 6Ckine and macrophage inflammatory protein-3 beta are potent chemoattractants for in vitro- and in vivo-derived dendritic cells. J Immunol 162 (1999) 3859-3864
34. Soto H., Wang W., Strieter R.M., Copeland N.G., Gilbert D.J., Jenkins N.A., et al. The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3. Proc Natl Acad Sci USA 95 (1998) 8205-8210
35. Merad M., Manz M.G., Karsunky H., Wagers A., Peters W., Charo I., et al. Langerhans cells renew in the skin throughout life under steady-state conditions. Nat Immunol 3 (2002) 1135-1141